"The Veris MR Monitor extends MEDRAD's line of outstanding MR compatible products. This product launch focuses on our commitment to the MR compatible monitoring market," said Gary Bucciarelli, senior vice president for the Magnetic Resonance Strategic Business Unit. "Veris offers our anesthesia, sedation, cardiac, and radiology customers what they have asked for - a reliable, full-featured monitor for all of their MR monitoring patients and strong support from MEDRAD's global field service and applications teams."

The design of Veris is based on customer and industry feedback that indicated unmet needs for a feature-rich, MR compatible patient monitor. To meet these needs, Veris offers large, color screens and a familiar user interface that allows rapid learning of the system. Five-lead ECG monitoring provides simultaneous display of up to six waveforms for efficient comparison. Specially designed accessories for adult, pediatric, and neonate patients give customers the opportunity to monitor patients of all sizes and ages. The Veris integral tray is designed for cable management and accessory storage while providing additional workspace. Power is supplied by an AC direct wall connection or by the extended life battery.

Veris is available in six configurations to meet specific customer needs for anesthesia, sedation, cardiac MR, research, and basic patient monitoring. MEDRAD worked closely in the development of Veris with Criticare Systems, Inc. (CSI), which is known for extensive expertise in monitoring systems and leading edge gas bench technology.
MEDRAD also offers Continuum, an MR compatible infusion system, which delivers critical medications during MRI exams, in addition to the Spectris Solaris© EP MR Injection System and an assortment of Leading ImageTM MR surface coils.

Veris is currently available in the United States and Europe and will be available in the rest of the world later this year. Veris, Leading Image, and Performance. For life. are trademarks and MEDRAD and Spectris Solaris are federally registered trademarks of MEDRAD, INC.

MEDRAD, INC. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and accessory products, and equipment services. Total 2004 revenues were $344 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is a U.S. affiliate of Schering AG, Germany (NYSE:SHR). For more information, visit MEDRAD's website at www.medrad.com.

Cautionary statement regarding forward-looking statements.
Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and MEDRAD's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. MEDRAD undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events, circumstances or otherwise.
###

More Industry Headlines